Bluhm Robyn
Department of Philosophy and Religious Studies, Old Dominion University, Norfolk, VA 23529, USA.
Perspect Biol Med. 2009 Spring;52(2):252-63. doi: 10.1353/pbm.0.0076.
Evidence-based medicine (EBM) ranks different medical research methods on a hierarchy, at the top of which are randomized controlled trials (RCTs) and systematic reviews or meta-analyses of RCTs. Any study that does not randomly assign patients to a treatment or a control group is automatically placed at a lower level on the hierarchy. This article argues that what matters is whether the treatment and control groups are similar with respect to potential confounding factors, not whether they got that way through randomization. Moreover, nonrandomized studies tend to have other characteristics that make them useful sources of evidence, in that they tend to last longer and to enroll more patients than do randomized trials. Replacing the sharp dichotomy between randomized and nonrandomized studies with a continuum from "clean" studies (which have high internal validity but whose results do not readily generalize to clinical practice) to pragmatic studies (which are designed to more closely reflect clinical practice) would also make a place for outcomes research and research using clinical databases, which are not included in the current hierarchy of evidence but which can provide important information about the safety and efficacy of treatments.
循证医学(EBM)将不同的医学研究方法按等级排序,位于顶端的是随机对照试验(RCT)以及RCT的系统评价或荟萃分析。任何未将患者随机分配至治疗组或对照组的研究都会自动处于该等级的较低层级。本文认为,重要的是治疗组和对照组在潜在混杂因素方面是否相似,而非它们是否通过随机化达到这种相似性。此外,非随机研究往往具有其他使其成为有用证据来源的特征,因为它们往往比随机试验持续时间更长且纳入的患者更多。用从“纯粹”研究(具有高内部效度但其结果不易推广至临床实践)到实用研究(旨在更紧密反映临床实践)的连续统取代随机研究与非随机研究之间的鲜明二分法,也将为结局研究以及使用临床数据库的研究留出空间,这些研究当前未被纳入证据等级体系,但可提供有关治疗安全性和有效性的重要信息。